Swedish Orphan Biovitrum AB (publ)

Stockholm Stock Exchange:SOBI.ST

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💉 Vaccines

Location

Sweden

Market Cap

USD 9.68 B

Share Price

USD 28.19

Avg Daily Volume

349,425

Change (1 day)

-3.10%

Change (1 year)

8.07%

Change (YTD)

-1.65%

Swedish Orphan Biovitrum AB (publ) Receivables for the year ending December 31, 2024: USD 664.29 M

Swedish Orphan Biovitrum AB (publ) Receivables is USD 664.29 M for the year ending December 31, 2024, a -4.70% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Swedish Orphan Biovitrum AB (publ) Receivables for the year ending December 31, 2023 was USD 697.02 M, a 18.85% change year over year.
Swedish Orphan Biovitrum AB (publ) Receivables for the year ending December 31, 2022 was USD 586.47 M, a 29.76% change year over year.
Swedish Orphan Biovitrum AB (publ) Receivables for the year ending December 31, 2021 was USD 451.96 M, a -17.59% change year over year.
Swedish Orphan Biovitrum AB (publ) Receivables for the year ending December 31, 2020 was USD 548.43 M, a 11.45% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Receivables	Inventory	Current Assets	Property, Plant, Equipment (Net)

Stockholm Stock Exchange: SOBI.ST

Swedish Orphan Biovitrum AB (publ)

CEO	Dr. Guido Oelkers Ph.D.
IPO Date	Sept. 15, 2006
Location	Sweden
Headquarters	Tomtebodavägen 23A
Employees	1,895
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💉 Vaccines

Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.